Vanguard Group’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,739,204
| Closed | -$48.7M | – | 4673 |
|
|
2022
Q1 | $48.7M | Sell |
1,739,204
-62,402
| -3% | -$1.71M | ﹤0.01% | 2319 |
|
|
2021
Q4 | $49.2M | Buy |
1,801,606
+19,717
| +1% | +$534K | ﹤0.01% | 2366 |
|
|
2021
Q3 | $48.5M | Buy |
1,781,889
+43,954
| +3% | +$1.09M | ﹤0.01% | 2373 |
|
|
2021
Q2 | $29.7M | Buy |
1,737,935
+34,279
| +2% | +$642K | ﹤0.01% | 2636 |
|
|
2021
Q1 | $35.6M | Buy |
1,703,656
+38,222
| +2% | +$882K | ﹤0.01% | 2492 |
|
|
2020
Q4 | $38.1M | Buy |
1,665,434
+35,829
| +2% | +$682K | ﹤0.01% | 2341 |
|
|
2020
Q3 | $26.6M | Sell |
1,629,605
-20,085
| -1% | -$364K | ﹤0.01% | 2318 |
|
|
2020
Q2 | $22.3M | Buy |
1,649,690
+15,235
| +0.9% | +$177K | ﹤0.01% | 2364 |
|
|
2020
Q1 | $19.4M | Buy |
1,634,455
+10,489
| +0.6% | +$233K | ﹤0.01% | 2300 |
|
|
2019
Q4 | $40.4M | Buy |
1,623,966
+8,798
| +0.5% | +$178K | ﹤0.01% | 2213 |
|
|
2019
Q3 | $27.5M | Buy |
1,615,168
+37,434
| +2% | +$681K | ﹤0.01% | 2320 |
|
|
2019
Q2 | $35.9M | Buy |
1,577,734
+62,289
| +4% | +$1.68M | ﹤0.01% | 2271 |
|
|
2019
Q1 | $48.7M | Buy |
1,515,445
+55,225
| +4% | +$1.71M | ﹤0.01% | 2094 |
|
|
2018
Q4 | $41.1M | Buy |
1,460,220
+83,150
| +6% | +$2.44M | ﹤0.01% | 2124 |
|
|
2018
Q3 | $39.6M | Buy |
1,377,070
+50,060
| +4% | +$1.5M | ﹤0.01% | 2258 |
|
|
2018
Q2 | $49.7M | Buy |
1,327,010
+24,425
| +2% | +$959K | ﹤0.01% | 2132 |
|
|
2018
Q1 | $51.2M | Buy |
1,302,585
+36,464
| +3% | +$1.33M | ﹤0.01% | 2061 |
|
|
2017
Q4 | $41M | Buy |
1,266,121
+49,083
| +4% | +$1.47M | ﹤0.01% | 2162 |
|
|
2017
Q3 | $37.9M | Buy |
1,217,038
+77,415
| +7% | +$2.29M | ﹤0.01% | 2180 |
|
|
2017
Q2 | $31.9M | Buy |
1,139,623
+71,750
| +7% | +$1.62M | ﹤0.01% | 2247 |
|
|
2017
Q1 | $18.3M | Buy |
1,067,873
+73,615
| +7% | +$1.03M | ﹤0.01% | 2476 |
|
|
2016
Q4 | $12M | Buy |
994,258
+74,205
| +8% | +$961K | ﹤0.01% | 2661 |
|
|
2016
Q3 | $14.6M | Buy |
920,053
+71,249
| +8% | +$1.07M | ﹤0.01% | 2508 |
|
|
2016
Q2 | $11M | Buy |
848,804
+30,105
| +4% | +$471K | ﹤0.01% | 2607 |
|
|
2016
Q1 | $15.6M | Buy |
818,699
+156,455
| +24% | +$2.83M | ﹤0.01% | 2396 |
|
|
2015
Q4 | $14.9M | Buy |
662,244
+37,878
| +6% | +$749K | ﹤0.01% | 2431 |
|
|
2015
Q3 | $14.6M | Buy |
624,366
+101,130
| +19% | +$2.79M | ﹤0.01% | 2421 |
|
|
2015
Q2 | $15M | Buy |
523,236
+320,495
| +158% | +$8.4M | ﹤0.01% | 2477 |
|
|
2015
Q1 | $5.24M | Buy |
202,741
+31,924
| +19% | +$730K | ﹤0.01% | 2984 |
|
|
2014
Q4 | $3.17M | Buy |
170,817
+144,711
| +554% | +$2.6M | ﹤0.01% | 3102 |
|
|
2014
Q3 | $404K | Buy |
+26,106
| New | +$393K | ﹤0.01% | 3772 |
|
Vanguard Group's XENT Position: Q2 2022 in Review
Vanguard Group sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 1,739,204 shares — an estimated $48.7M sold.
Vanguard Group first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $51.2M in Q1 2018. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Vanguard Group reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Vanguard Group sold 1,739,204 Intersect ENT, Inc shares in Q2 2022, an estimated $48.7M.
- Vanguard Group first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
- Vanguard Group's Intersect ENT, Inc position peaked at $51.2M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.